Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4893989 | 0.85 | ACHE (0.65) | KDM4EPOLBSMN1; SMN2EPHX1L3MBTL3 | |
| SCHEMBL27240744 | 0.83 | GAA (0.58) | GAAPOLBSMN1; SMN2CHRNB2CHRNB4 | |
| SCHEMBL13607630 | 0.82 | KMT2A (0.65) | SMN1; SMN2EPHX2L3MBTL3 | |
| SCHEMBL30059026 | 0.81 | RECQL (0.65) | KDM4EGAAPOLBRECQLCYP3A4 | |
| SCHEMBL22119220 | 0.81 | KDM4E (0.59) | KDM4EGAAPOLBRECQLCYP3A4 | |
| SCHEMBL13744553 | 0.79 | ACHE (0.72) | KDM4EGAAPOLBRECQLTP53 | |
| SCHEMBL4703332 | 0.79 | KDM4E (0.57) | KDM4EGAAPOLBRECQLCYP3A4 | |
| SCHEMBL4703329 | 0.79 | KDM4E (0.61) | KDM4EGAAPOLBRECQLCYP3A4 | |
| SCHEMBL8293030 | 0.78 | MEN1 (0.63) | KDM4EPOLBSMN1; SMN2 | |
| SCHEMBL16783134 | 0.78 | ABCG2 (0.58) | KDM4EGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812231-B2 | INHIBITING ACTIVATED BLOOD-COAGULATION FACTOR X | AJINOMOTO CO., INC. (JP) | 2004-11-02 | — | — | US | claimed |
| US-20020107290-A1 | Benzamidine derivative | AJINOMOTO CO., INC. (JP) | 2002-08-08 | — | — | US | claimed |
| US-6410538-B2 | ANTICOAGULANT OR AN AGENT FOR TREATING OR PREVENTING THROMBI OR EMBOLI | AJINOMOTO CO., INC. (JP) | 2002-06-25 | — | — | US | claimed |
| US-20010056123-A1 | Anticoagulant or an agent for treating or preventing thrombi or emboli | AJINOMOTO CO., INC (JP) | 2001-12-27 | — | — | US | claimed |
| CN-1311771-A | Benzamidine derivative | AJINOMOTO KK (JP) | 2001-09-05 | — | — | CN | claimed |
| EP-1086946-A1 | BENZAMIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2001-03-28 | — | — | EP | claimed |
| US-6812231-B2 | INHIBITING ACTIVATED BLOOD-COAGULATION FACTOR X | AJINOMOTO CO., INC. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20020107290-A1 | Benzamidine derivative | AJINOMOTO CO., INC. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-6410538-B2 | ANTICOAGULANT OR AN AGENT FOR TREATING OR PREVENTING THROMBI OR EMBOLI | AJINOMOTO CO., INC. (JP) | 2002-06-25 | — | — | US | disclosed |
| US-20010056123-A1 | Anticoagulant or an agent for treating or preventing thrombi or emboli | AJINOMOTO CO., INC (JP) | 2001-12-27 | — | — | US | disclosed |
| CN-1311771-A | Benzamidine derivative | AJINOMOTO KK (JP) | 2001-09-05 | — | — | CN | disclosed |
| EP-1086946-A1 | BENZAMIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2001-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107290-A1 | Benzamidine derivative | SERPINE1, SERPINC1, TFPI | KDM4E 3660/4885GAA 229/4885POLB 2726/4885 |
| US-20010056123-A1 | Anticoagulant or an agent for treating or preventing thrombi or emboli | SERPINC1, SERPINE1, F2 | KDM4E 4253/4885GAA 228/4885POLB 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.